Kytopen develops a continuous flow transfection platform, Flowfect, that combines mechanical, electrical, and chemical forces to engineer therapeutic cells. The company says its technology can deliver hundreds of billions of engineered cells in minutes and is designed to integrate into closed GMP workflows. Its product family includes Flowfect Tx® GMP and Flowfect Discover™ 96-well systems to support feasibility, optimization, and scale-up to clinical and commercial manufacturing. Kytopen has disclosed strategic partnerships with biotechnology firms, CDMOs, and cell therapy medical centers to advance cell therapy development and manufacture. The company plans to use new investment to expand commercial operations across the U.S. and Europe and to invest in infrastructure to support partner programs. Management emphasizes the platform's scalability, gentleness on cells, and applicability across a range of cell types and payloads.

Total raised

$34M

Funding rounds

3

Latest round

Series A

Latest activity

Sep 2021